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Approximately 90% of all human cancers, in which some deregulation 
of cell cycle arrest or programmed cell 
death has occurred, express telomerase, a 
ribonucleoprotein whose activity is nor-
mally turned off in healthy somatic tis-
sues. Additionally, small populations of 
self-renewing stem cells, such as hema-
topoietic stem cells, skin and hair fol-
licle basal layer cells and intestinal basal 
crypt cells, have been shown to retain 
telomerase activity. Conversely, heredi-
tary defects that result in shortened 
telomeres in humans have been shown 
to manifest most often as bone marrow 
failure or pulmonary fibrosis, along with 
a myriad of other symptoms, likely due 
to the loss of the stem and/or progeni-
tor cells of affected tissues. The aim of 
this review is to highlight our knowledge 
of the mechanisms of telomere mainte-
nance that contribute to the pathology of 
human disease caused by dysfunctional 
telomere homeostasis. Specifically, a new 
role for the SNM1B/Apollo nuclease in 
the pathologies of Hoyeraal-Hreidarsson 
syndrome will be discussed. 
Introduction
The vitality of a cell lineage encompasses 
an intricate balance between forces that 
promote indefinite proliferative poten-
tial and forces that promote apoptosis or 
senescence. The length of a tract of G-rich 
double-stranded repetitive sequence found 
at the ends of linear chromosomes, termed 
telomeres, is a major determinant of the 
replicative limit of some human somatic 
cell types.1 Telomeres erode with every cell 
division due to the inability of canonical 
DNA polymerases to completely replicate 
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the 3´ end of each parental DNA strand. 
Most eukaryotes express the enzyme 
telomerase to combat telomere erosion. 
Telomerase is a ribonucleoprotein that 
adds a unique sequence onto the terminal 
3´ overhang present at chromosome ends 
via its reverse transcriptase catalytic sub-
unit, hTERT, with the aid of an RNA sub-
unit, hTR, which provides the template 
for the telomere sequence.2 Canonical 
telomere binding proteins TRF1, TRF2, 
POT1, TPP1, RAP1 and TIN2, collec-
tively termed the shelterin complex in 
mammals, modulate telomere length by 
negatively and positively regulating telom-
erase activity at telomeres.3 A multitude of 
other proteins, involved in processes such 
as DNA damage response, cell cycle regu-
lation and RNA metabolism, play crucial 
roles in telomere maintenance by promot-
ing the biogenesis or activity of telomer-
ase or the integrity of the telomeric DNA 
itself. Telomeres are thought to evade a 
DNA damage response by adopting a 
conformation, termed T loop, where the 
3´ overhang loops back to form a strand 
invasion intermediate within the double-
stranded telomere duplex.4 Uncapped or 
dysfunctional telomeres can be visualized 
through Telomere Dysfunction-Induced 
Foci (TIFs), which are comprised of sev-
eral proteins and chromatin changes that 
coincide with telomeres upon the incite-
ment of a DNA damage signal. Such foci 
may correspond to triggers of apoptosis or 
senescence.5
Telomerase Dysfunction  
in Human Disease
Dyskeratosis congenita (DC) was the 
first disease found to be caused by 
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promote stabilization and assembly of the 
entire telomerase complex, and biochemi-
cal purification of human telomerase has 
shown a close physical interaction with 
all four proteins.12 Definitive support for 
telomerase complex dysfunction playing 
a causal role in DC pathology was pro-
vided by identification of disease-causing 
mutations in hTERT and hTR in DC 
patients.13,14 Families with mutations in 
hTR or hTERT display anticipation, where 
successive generations inherit shorter telo-
meres and therefore exhibit initial DC 
implicated aberrantly shortened telomeres 
as the causal defect in the X-linked syn-
drome.7 Dyskerin, a protein that associates 
with small nucleolar RNAs (snoRNAs), 
interacts with the box H/ACA domain 
structure found at the 3’ end of human 
telomerase RNA, hTR.8,9 Aside from dys-
kerin, mutations in other snoRNA-associ-
ated proteins NOP10 and NHP2, which 
are required for telomerase biogenesis, 
have been identified in DC patients.10,11 
The box H/ACA RNA binding proteins 
dyskerin, NHP2, NOP10 and GAR1 
dysfunctional telomere maintenance in 
humans. Around 80% of DC patients 
exhibit the classic triad of diagnostic 
muco-cutaneous symptoms (abnormal 
skin pigmentation, nail dystrophy and oral 
leukoplakia) by an average of 10 years of 
age. They are over 90% likely to develop 
bone marrow failure, which causes almost 
70% of patient deaths by 40 years of age. 
An additional 20% of patients succumb to 
either pulmonary complications or malig-
nancy.6 In 1998, mutations in DKC1, 
which encodes the protein dyskerin, first 
Figure 1. Several forms of telomere dysfunction—such as progressive or rapid telomere loss or hypothetical telomere doublets—manifest in varied 
severity of diseases of bone marrow failure in humans.
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overexpression of TIN2 lacking its car-
boxy-terminus leads to telomere attrition 
in human cells, whereas overexpression of 
TIN2 lacking its amino-terminus leads 
to telomere extension.37 Thus, analysis of 
mutant TIN2 proteins that elicit human 
telomere dysfunction may reveal vari-
ants that exhibit effects similar to that 
of in vitro C-terminal truncation of this 
protein.
The former studies of TINF2 defi-
ciency suggest that other shelterin com-
ponents, TRF2, TRF1, RAP1, TPP1 and 
hPOT1, may be plausible candidates for 
the dysfunction seen in patients suffering 
from inherited bone marrow failure dis-
orders. For example, several lines of evi-
dence allude to the possible involvement 
of hPOT1 in the pathologies of these dis-
eases. mPot1b-/- mice, which lack one of 
two mouse POT1 genes, display a massive 
increase in apoptosis in highly proliferative 
cells of the testes and intestine.38 In the 
context of a telomerase haploinsufficiency, 
mPot1b-/- phenotypes are exacerbated and 
manifest in reduced body size as well as 
dyskeratosis congenita-like symptoms of 
hyperpigmentation of the extremities and 
nail dystrophy.38 These mice also have a 
severely reduced lifespan accompanied 
by symptoms suggestive of bone marrow 
failure towards the end of their life. While 
total telomere length is unaffected in 
the liver tissue of mPot1b-/-, mTR+/- mice, 
immortalized mPot1b-/-, mTR+/- mouse 
embryonic fibroblasts (MEFs) exhibit a 
loss of overall telomere length.38 An inde-
pendent study has shown that mouse 
POT1 proteins protect telomeres from 
initiating DNA damage response signal-
ing and from nuclease-mediated erosion of 
the 5’ end of the chromosome terminus.39
hPOT1 binds to single-stranded telo-
meric DNA and is tethered to the double-
stranded portion of the telomere through 
its shelterin binding partners.40-42 hPOT1 
has been shown to positively and nega-
tively regulate telomere length, and its 
knock-down consistently led to DNA 
damage response signaling at telomeres, 
affirming a role in telomere protection.43-45 
While hPOT1 binding to the terminal sin-
gle-stranded 3’ end of a telomeric substrate 
precludes telomerase extension, interaction 
of hPOT1 with TPP1 can stimulate telom-
erase processivity.46,47 TPP1 itself has been 
with POT1, TRF1 and TRF2 to perform 
various tasks at human telomeres.28,29 In 
contrast to telomerase deficiency, WRN 
dysfunction affects different tissues or cel-
lular compartments, eliciting loss of hair, 
cataracts, diabetes mellitus and osteopo-
rosis accompanied by premature death 
at a median age of 54 due to cardiovas-
cular disease.30 Thus, WRN deficiency 
may result in telomeric stress that affects 
a unique subset of cell types.
Dysfunctional Telomere Capping 
Proteins in Human Disease
Deleterious mutations in single alleles of 
the gene TINF2, which encodes one of the 
shelterin complex proteins, TIN2, were 
identified in several patients diagnosed 
with DC and ataxia-pancytopenia.31,32 
TIN2 serves as a scaffold for shelterin pro-
teins TPP1 and POT1 by tethering them 
to telomeric double-stranded DNA via 
interactions with TRF1 and TRF2.33,34 
DC patients with TINF2 mutations 
exhibit an earlier onset and a higher sever-
ity of symptoms than most patients with 
hTR or hTERT mutations.35 The dramati-
cally short telomeres seen in cells from 
patients carrying mutated TINF2 could 
be symptomatic of rapid telomere dys-
function due to telomere uncapping. This 
is unlike the progressive telomere shorten-
ing seen over generations in patients with 
dysfunctional telomerase, because TINF2 
mutations arise de novo in the germ cells 
of parents of DC patients. Thus, acceler-
ated telomere shortening due to telomere 
deprotection is the likely mechanism at 
fault since these patients inherit telomeres 
of normal length. Even though a dramatic 
reduction of in vitro telomerase activity has 
been reported for one ataxia-pancytopenia 
patient, unperturbed hTR levels in several 
DC patients with TINF2 mutations sup-
ports a telomere uncapping/deprotection 
pathology in most cases.31,32 Inconsistent 
with what is seen in the former patients, 
TIN2 has been shown to act as a nega-
tive regulator of telomerase in vitro, where 
siRNA-mediated knock-down of TIN2 in 
human cells elicits progressive telomere 
elongation.36 The basis of this discrepancy 
remains unclear and requires further anal-
ysis of the effect of TIN2 mutations on 
protein function in patients. For example, 
symptoms earlier in life.15,16 Patients also 
exhibit shorter telomeres at every age com-
pared to healthy individuals.17
Most hTR and hTERT mutations that 
cause disease do so when heterozygous, 
indicating haplo-insufficent or dominant-
negative effects on telomerase function.18,19 
Patients who are homozygous or multiply 
heterozygous for mutant alleles of hTERT 
or hTR display an exacerbated reduction of 
in vitro telomerase activity, although telo-
mere length, as opposed to the presence of 
one or two mutant alleles in affected indi-
viduals, serves as the most reliable predic-
tor of symptom severity.20 In fact, 30 out 
of 72 families with individuals diagnosed 
with DC harbor the same DKC1 muta-
tion but exhibit a heterogeneous clinical 
presentation and severity of symptoms, 
likely due to variations in telomere length 
at individual chromosome ends or in poly-
morphisms in other genes that affect rates 
of telomere erosion during development.21 
Lymphoblastoid cell lines derived from 
DC patients exhibit accelerated telomere 
shortening that causes increased levels of 
cell death, which may represent an in vivo 
mechanism of dysfunction where stem 
cell depletion manifests in the pathologies 
seen in these patients.22
The high prevalence of aplastic ane-
mia (AA) and pulmonary failure in DC 
patients led to an investigation of whether 
dysfunctional telomere replication plays 
a more general role in these pathologies. 
Indeed, mutations in hTR were found in 
several AA patients, whose telomeres were 
shorter than healthy controls.23 Patients 
suffering from other bone marrow disor-
ders such as paroxysmal nocturnal hemo-
globinuria (PNH) and myelodysplasia 
(MDS) also were found to harbor hTR 
mutations.24 More recently, mutations in 
hTR and hTERT were identified in patients 
diagnosed with idiopathic pulmonary 
fibrosis (IFP), along with reports suggest-
ing that liver cirrhosis may also occur as a 
consequence of telomerase deficiency.25-27
Note that telomere dysfunction may 
result in pathologies that are distinct from 
those observed in bone marrow failure 
and related disorders caused by telomerase 
deficiency. For example, the rare accel-
erated aging disease Werner syndrome 
results from mutations in the WRN heli-
case, which has been shown to cooperate 
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Recently, a role has been proposed for 
SNM1B/Apollo in telomere protection 
through generation of 3’ single-stranded 
overhangs via 5’ C-strand resection at 
newly replicated blunt leading-strand telo-
meres, which are subjected to non-homolo-
gous end joining (NHEJ)-mediated fusion 
in the absence of SNM1B/Apollo.62,63 
SNM1B/Apollo-/- MEFs exhibit lead-
ing-strand chromatid-type fusions and 
reduced overall 3’ overhang intensity, 
phenotypes that are suppressed when cells 
are reconstituted with wild-type SNM1B/
Apollo, but not with SNM1B/Apollo 
lacking its TRF2-interacting domain or 
nuclease activity. Thus, the 5’ to 3’ nucle-
ase activity of SNM1B/Apollo, as well as 
its physical presence at telomeres, are cru-
cial elements of telomere protection and 
overhang maintenance.62,63 The lack of 
increased sensitivity of cells transformed 
with Apollo-Δ to IR or ICL-inducing 
agents indicates that these cells likely 
retain proper Apollo nuclease activity, 
which is required for its DNA repair func-
tions, but that this activity is unable to 
function properly at the telomere, proba-
bly due to the inability of Apollo-Δ to bind 
TRF2, which not only tethers SNM1B/
Apollo to the telomere but also stimulates 
its nuclease activity.61 Overexpression of 
nuclease-inactive SNM1B/Apollo in wild-
type human cells resulted in an increase in 
TIFs and accelerated onset of senescence, 
similar to what is seen in cells transformed 
with Apollo-Δ.61
It is likely that the dysfunction caused 
by the splice variant Apollo-Δ manifests 
in the HH patient as a defect in telomere 
capping, or in the process that prevents 
telomere doublets, rather than a defect 
in telomerase itself. The maladies of this 
Hoyeraal-Hreidarsson patient present as 
more severe in penetrance and age-of-onset 
than those exhibited by DC patients, sim-
ilar to the severity of disease that patients 
with mutations in TINF2 experience and 
allude to the importance of telomere pro-
cessing and capping in early onset forms of 
telomere dysfunction.
Analysis of the other two SNM1 
family genes has revealed that SNM1A 
functions in ICL repair and has been 
implicated as a tumor suppressor, but has 
no known role at telomeres.53 SNM1C/
Artemis has been extensively studied 
is the case for even greater proportions of 
idiopathic pulmonary fibrosis and aplastic 
anemia patients, where no causal polymor-
phisms were found in described telomere 
maintenance genes (hTR, hTERT, NOP10, 
NHP2, DKC1 and TINF2). Recently, one 
of the SNM1 family genes in humans, 
SNM1B/Apollo, which possesses the 
ancestral SNM1 function of interstrand 
cross-link (ICL) repair and interacts with 
the shelterin component TRF2, has been 
implicated as a causal factor in the symp-
toms of telomere dysfunction in a patient 
diagnosed with Hoyeraal-Hreidarsson 
(HH) syndrome.54-57 HH syndrome is 
characterized by more severe and earlier-
onset DC-associated abnormalities as well 
as additional phenotypes including cere-
bellar hypoplasia, microcephaly, immuno-
deficiency, AA and growth retardation.58 
While HH can be caused by homozygous 
mutations in hTERT and hemizygous 
mutations in DKC1, this patient harbors a 
dominant-negative splice form of Snm1B/
Apollo, “Apollo-Δ”, and fibroblasts from 
this patient exhibited similar telomere 
lengths to that of normal age-matched 
controls.59 Thus, critically shortened telo-
meres may not be the direct cause of dete-
rioration of affected tissues in this patient, 
consistent with reports for other HH 
patients where telomere shortening was not 
reliably observed.60 However, additional 
forms of telomere dysfunction, includ-
ing shortened 3’ overhangs, Telomere 
Dysfunction-Induced Foci (TIFs), end-to-
end chromosome fusions and unusual telo-
mere doublet structures were apparent in 
patient fibroblasts, suggesting that (one of) 
these phenotypes, rather than telomere 
shortening, may be directly relevant to 
disease.56,60 Specifically, the higher fre-
quency of telomere doublets, as compared 
to telomere chromatid fusions, in both 
fibroblasts transformed with Apollo-Δ as 
well as in cultured fibroblasts from this 
HH patient, implicates these doublets as a 
causal factor in the observed dysfunctional 
phenotypes.56 Moreover, an independent 
study has indicated that cells transformed 
with nuclease-dead versions of SNM1B/
Apollo also exhibit significant increases 
in telomere doublets, confirming a role 
for SNM1B/Apollo in preventing the for-
mation of these structures, whose nature 
remains uncertain.61
shown to possess dual roles in telomere 
length regulation, where cells transformed 
with TPP1 lacking its OB-fold exhibited 
telomere shortening while cells trans-
formed with TPP1 lacking the first 86 
amino acids of the N-terminus exhibited 
extensive telomere elongation.48 Two Pot1 
proteins in Arabidopsis thaliana take on dif-
ferent roles in telomere length regulation, 
where AtPot1a associates with the telomer-
ase complex and is essential for telomerase 
activity in vivo, while AtPot1b functions in 
chromosome end protection.49,50
Recently, a protein with POT1 homol-
ogy in C. elegans, MRT-1, was shown to 
be essential for telomere maintenance in 
vivo.51 MRT-1 is a dual-domain protein 
with homology to the second OB-fold 
of hPOT1 and to the nuclease domain 
of the SNM1 family of proteins, which 
function in DNA damage repair and cell 
cycle checkpoint response.52,53 A muta-
tion in the OB-fold of mrt-1(yp2) not only 
abolishes the ability of MRT-1 to bind 
single-stranded DNA in vitro and abro-
gates telomere replication in vivo, but also 
results in increased susceptibility to ICL-
induced damage. The mild deficiency in 
ICL repair seen in this mutant might be 
caused by a defect in interacting with sub-
strates, due to a mutant OB-fold. While 
the role of the SNM1 nuclease domain 
of MRT-1 in telomere maintenance is 
presently unclear, these results highlight 
the crucial role for the POT1-derived 
OB-fold domain of MRT-1 in promot-
ing telomerase activity. Consistently, 
AtPot1a promotes telomerase RNP activ-
ity in Arabidopsis and POT1/TPP1 may 
promote telomerase activity in a context-
dependent manner in human cells.47,50
Together, studies of POT1 homologs 
in diverse organisms suggest that reduced 
or altered hPOT1 function in certain 
human tissues might cause progressive 
telomere shortening, via effects on either 
telomere capping or telomerase function, 
which could precipitate lethal failure of 
the hematopoietic or pulmonary systems.
SNM1B/Apollo is Involved in the 
Pathology of Bone Marrow Failure 
Syndrome Hoyeraal-Hreidarsson
Genes responsible for almost half of DC 
cases remain molecularly undefined, as 
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due to its role in V(D)J recombination, 
which is dependent on its collaboration 
with DNA-PKcs.53 Artemis deficiency in 
humans leads to human severe combined 
immunodeficiency (SCID) syndrome, 
which is mimicked in mice that exhibit 
SCID-like symptoms when Artemis is 
deficient.53 Artemis has been implicated 
in telomere maintenance through several 
observations where Artemis-null mouse ES 
lines exhibited telomeric fusions, general 
genomic instability and telomere shorten-
ing.64,65 However, this is a mild telomere 
fusion phenotype in comparison to that 
seen for lethal SNM1B/Apollo mutations. 
Although a single SNM1 homolog exists 
in C. elegans, the MRT-1 POT1 OB-fold/
SNM1 fusion protein, null alleles of the 
mrt-1 gene yield a progressive telomere 
erosion phenotype that is indistinguish-
able from that of telomerase mutants. 
Significant levels of end-to-end fusions 
are not apparent in early generation mrt-1 
strains with long telomeres (Ahmed S, 
unpublished), suggesting that a role in 
telomere capping or leading-strand resec-
tion is derived for or otherwise specific 
to SNM1B in vertebrates. Nevertheless, 
a role in telomere biology is suggested for 
the SNM1 domain of MRT-1 given its 
fusion to the telomerase-promoting POT1 
OB-fold.
Conclusion
The discovery of causal mutations in pro-
teins involved in telomerase-mediated telo-
mere maintenance, hTR, hTERT, DKC1, 
NOP10, NHP2, as well as in proteins that 
promote telomere capping, TINF2 and 
Apollo/SNM1B, in patients with debili-
tating bone marrow failure syndromes 
contributes to our understanding of how 
telomere biology confers disease pathol-
ogy in humans. Unusual telomere capping 
abnormalities that do not perturb telomere 
length but affect replication and DDR sig-
naling at telomeres can result in the cull-
ing of stem or progenitor cell populations, 
particularly in hematopoietic and pulmo-
nary systems, with lethal consequences. 
Mutations in telomere binding proteins 
or proteins that transiently interact with 
telomeres to promote telomere capping, 
can lead to rapid and severe symptoms 
in affected individuals.66-68 Likewise, 
mutations in the many genes that function 
in telomerase complex stability, biogenesis 
or recruitment to telomeres can yield either 
a subset or the full spectrum of DC-like 
symptoms that are typically milder than 
those seen in HH patients and take mul-
tiple generations to cause strong effects 
(Fig. 1).69-72 Elucidation of the respective 
disease contributions of telomeric dou-
blets, which commonly occur in cells that 
harbor Apollo-Δ, in comparison to minor 
but possibly significant levels of chromo-
some fusion, represent important ques-
tions in the field. These questions may be 
solved by continued analysis of cells from 
a spectrum of human patients with dys-
functional telomeres in conjunction with 
basic research in telomere biology.
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